Abstract

The tumor microenvironment (TME) may influence both cancer progression and therapeutic response. In breast cancer, particularly in the aggressive triple‐negative/basal‐like subgroup, patient outcome is strongly associated with the tumor's inflammatory profile. Tumor‐associated macrophages (TAMs) are among the most abundant immune cells in the TME, shown to be linked to poor prognosis and therapeutic resistance. In this study, we investigated the effect of the metastasis‐ and inflammation‐associated microenvironmental factor S100A4 on breast cancer cells (BCCs) of different subtypes and explored their further interactions with myeloid cells. We demonstrated that extracellular S100A4 activates BCCs, particularly the basal‐like subtype, to elevate secretion of pro‐inflammatory cytokines. The secreted factors promoted conversion of monocytes to TAM‐like cells that exhibited protumorigenic activities: stimulated epithelial–mesenchymal transition, proliferation, chemoresistance, and motility in cancer cells. In conclusion, we have shown that extracellular S100A4 instigates a tumor‐supportive microenvironment, involving a network of cytokines and TAM‐like cells, which was particularly characteristic for basal‐like BCCs and potentiated their aggressive properties. The S100A4–BCC–TAM interaction cascade could be an important contributor to the aggressive behavior of this subtype and should be further explored for therapeutic targeting.

Highlights

  • Breast cancer (BC) is the most frequent cancer in women

  • We explored the effect of extracellular S100A4 on breast cancer cells (BCCs) of different subtypes and investigated their further interactions with myeloid cells

  • We used in silico methods to evaluate the percentage of tumor cells and abundance of stroma and immune cell infiltration in tumor samples from The Cancer Genome Atlas (TCGA)’s BC cohort (n = 1052)

Read more

Summary

Introduction

Breast cancer (BC) is the most frequent cancer in women. The prognosis and choice of treatment is heavily dependent on the subtype of BC. The majority of the tumors express hormone (estrogen and progesterone) receptors and/or human epidermal growth factor receptor 2 (HER2), allowing targeted treatment using antihormone or anti-HER2 therapies. For tumors lacking these receptors, that is, triple-negative breast cancer (TNBC), chemotherapy is the only treatment option, resistance usually develops. Like classically activated M1 macrophages, TAMs resemble the M2 phenotype and are protumorigenic, that is, can suppress antitumor immunity, promote angiogenesis, stimulate invasion, and facilitate resistance to therapy (Condeelis and Pollard, 2006; Ruffell and Coussens, 2015). Further development of TAM-directed therapies would benefit from better understanding of the complex mechanisms regulating their fate and functions

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.